Related Experiment Videos
Biochemical marker discovery, testing and evaluation for facilitating OA drug discovery and development
Anne-Christine Bay-Jensen1, Christian S Thudium1, Oreste Gualillo2
1Rheumatology, Biomarkers and Research, Nordic Bioscience A/S, Herlev, Denmark.
Drug Discovery Today
|October 18, 2017
Summary
Identifying biomarkers for osteoarthritis (OA) subtypes is crucial for developing effective disease-modifying OA drugs (DMOADs). Objective patient phenotyping tools are needed to improve targeted treatments and clinical trial recruitment for this common joint disease.
Area of Science:
- Biomedical research
- Drug development
- Osteoarthritis research
Background:
- Osteoarthritis (OA) is the most prevalent joint disease, presenting significant research and pharmaceutical development opportunities.
- Current OA treatments are often poorly targeted due to the disease's heterogeneity.
- Developing disease-modifying osteoarthritis drugs (DMOADs) faces challenges in patient stratification for clinical trials.
Purpose of the Study:
- To highlight the urgent need for objective biomarker tools for patient phenotyping in osteoarthritis.
- To emphasize how identifying OA subtypes can facilitate drug development from discovery to clinical stages.
- To address the limitations of current approaches in developing targeted OA treatments.
Main Methods:
- This study is a conceptual overview and does not involve new experimental data.
- It analyzes the challenges in current osteoarthritis research and drug development pipelines.
- It discusses the potential impact of biomarker discovery for patient phenotyping.
Main Results:
- The heterogeneity of osteoarthritis subtypes complicates traditional treatment development.
- Current methods lead to suboptimal treatment targeting and difficulties in patient recruitment for trials.
- There is a clear need for objective biomarkers to define patient subgroups.
Conclusions:
- Objective biomarker tools are essential for accurate patient phenotyping in osteoarthritis.
- Improved phenotyping will accelerate the development of effective DMOADs.
- Advancing OA treatment requires a shift towards precision medicine approaches.